Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
Sponsor: Priovant Therapeutics, Inc.
Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2025-04-09
Completion Date
2026-12
Last Updated
2025-05-18
Healthy Volunteers
No
Conditions
Interventions
Oral Brepocitinib
Drug: Oral Brepocitinib
Oral Placebo
Drug: Oral Placebo
Locations (4)
Clinical Trial Site
San Francisco, California, United States
Clinical Trial Site
Durham, North Carolina, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Madison, Wisconsin, United States